BioNTech’s Bold Leap: From COVID-19 Vaccine Fame to Cancer Therapy Trailblazer
BioNTech is shifting focus from COVID-19 vaccines to mRNA-based cancer therapies amidst declining vaccine demand. In the last quarter of 2024, BioNTech's earnings per share dropped to €1.08, with overall…